References
- ANSM Agence Nationale de sécurité du médicament et des produits de santé. Résumé des Caractéristiques du Produit - IMOVANE® (zopiclone). 2016. [Cited 2016 Dec 19]. Available from: http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid=61435939&typedoc=R&ref=R0279188.htm
- ANSM Agence Nationale de sécurité du médicament et des produits de santé. Résumé des Caractéristiques du Produit - STILNOX® (zolpidem). 2016. [Cited 2016 Dec 19]. Available from: http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid=63179285&typedoc=R&ref=R0286012.htm
- Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59:865–889.
- Dell’Osso B, Albert U, Atti AR, et al. Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatr Dis Treat. 2015;11:1885–1909.
- Baumevieille M, Miremont G, Haramburu F, et al. The French system of evaluation of dependence: establishment in a legal system. Therapie. 2001;56:15–22.
- Victorri-Vigneau C, Gerardin M, Rousselet M, et al. An update on zolpidem abuse and dependence. J Addict Dis. 2014;33:15–23.
- Victorri-Vigneau C, Feuillet F, Wainstein L, et al. Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. Eur J Clin Pharmacol. 2013;69:1965–1972.
- Landreat MG, Vigneau CV, Hardouin JB, et al. Can we say that seniors are addicted to benzodiazepines? Subst Use Misuse. 2010;45:1988–1999.
- Victorri-Vigneau C, Wainstein L, Guillet JY, et al. Diagnostic of pharmacodependence: comparison between patients and doctors approaches. Therapie. 2012;67:167–172.
- Victorri-Vigneau C, Gerardin-Marais M, Mallaret M, et al. Example of complementarities between evaluation of the Regional Pharmacovigilance Department and Centre of Evaluation and Information on Pharmacodependence. Therapie. 2008;63:468–471.
- Victorri-Vigneau C, Dailly E, Veyrac G, et al. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007;64:198–209.
- Victorri-Vigneau C, Hardouin JB, Rousselet M, et al. Multicentre study for validation of the French addictovigilance network reports assessment tool. Br J Clin Pharmacol. 2016;82:1030–1039.
- APA. DSM-IV. Manuel diagnostique et statistique des troubles mentaux. 4ème ed. Paris:Trad Paris Masson; 1996.
- ANSM Agence Nationale de sécurité du médicament et des produits de santé. Appels à projet de recherche - résultats de l'appel à projet 2012. 2016. [Cited2016Dec19]. Available from: http://ansm.sante.fr/L-ANSM2/Appels-a-projets-de-recherche/Resultats-de-l-appel-a-projets-2012/(offset)/6.
- Lebart L, Morineau A, Piron M. Statistique exploratoire multidimensionnelle. Paris:Dunod; 1995.
- Hajak G, Muller WE, Wittchen HU, et al. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98:1371–1378.
- Andersen AB, Frydenberg M. Long-term use of zopiclone, zolpidem and zaleplon among Danish elderly and the association with sociodemographic factors and use of other drugs. Pharmacoepidemiol Drug Saf. 2011;20:378–385.
- Yen CF, Yen CN, Ko CH, et al. Correlates of dependence and beliefs about the use of hypnotics among zolpidem and zopiclone users. Subst Use Misuse. 2015;50:350–357.
- Gerardin M, Victorri-Vigneau C, Guerlais M, et al. Benzodiazepines consumption: does dependence vary with age? Subst Use Misuse. 2014;49:1417–1425.
- Cubala WJ, Landowski J, Wichowicz HM. Zolpidem abuse, dependence and withdrawal syndrome: sex as susceptibility factor for adverse effects. Br J Clin Pharmacol. 2008;65:444–445.
- U.S. Food and Drug Administration F. FDA drug safety communication: risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2016. [Cited 2017 Jun 14]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm334033.htm
- Cubala WJ, Wiglusz M, Burkiewicz A, et al. Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor. Eur J Clin Pharmacol. 2010;66:955; author reply 7–8.
- McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3:587–592.
- ANSM Agence Nationale de sécurité du médicament et des produits de santé. Compte-rendu de la Commission des Stupéfiants et des Psychotropes du 21 novembre 2013. 2013. ANSM Agence Nationale de sécurité du médicament et des produits de santé. Appels à projet de recherche - résultats de l'appel à projet 2012. 2016. [Cited 2016 Dec 19]. Available from: http://ansm.sante.fr/L-ANSM2/Appels-a-projets-de-recherche/Resultats-de-l-appel-a-projets-2012/(offset)/6.Available from: http//ansm.sante.fr/var/ansm_site/storage/original/application/ab78fffb49da3bf1ef109c45afc4a72a.pdf.
- Wainstein L, Victorri-Vigneau C, Sebille V, et al. Pharmacoepidemiological characterization of psychotropic drugs consumption using a latent class analysis. Int Clin Psychopharmacol. 2011;26:54–62.